Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs Tirzepatide in Obesity (REDEFINE 4)
NCT06131437Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in obesity, sponsored by Novo Nordisk. Started Nov 2023; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06131437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06131437.